IQVIA艾昆纬：2024年全球医药研发全景展望报告（英文版）

R&D funding levels have rebounded in 2023 after a steep decline from the peak seen in 2020-21. While the number of deals has fallen, high profile and high value deals indicate robust interest from investors and innovators in the next generation of therapies. Biopharma funding levels rebounded to $72Bn in 2023, up from $61Bn in 2022, although still well below the levels in 2020-21. M&A activity jumped to $140Bn from $78Bn in 2022, while median deal value dipped for the second year. The